11.01.04
Indication: Macular degeneration
Source: 2004 American Academy of Ophthalmology and European Society of Ophthalmology Joint Meeting, New Orleans, LA
Research: Investigators studied the effect of Phototrop® on 106 patients in the early stages of age-related macular degeneration (AMD). The objective of the double-blind, placebo-controlled, single-center study carried out in Hungary was to determine how Phototrop influenced visual functions of patients ages 55 to 70 years with early AMD after 12 months of treatment compared to the placebo group. The study was also aimed at evaluating changes in fundus alterations or the drusen-covered areas. Finally, the safety of the product was considered.
Results: The researches found that the patients experienced a statistically significant decrease in drusen (yellow deposits that accumulate under the retina). They concluded that the findings justify an assumption that an appropriate combination of mitotropic compounds (those that influence mitochondrial metabolism) improves visual functions in early AMD and diminishes the risk of vision loss associated with more advanced stages of the disease.
Source: 2004 American Academy of Ophthalmology and European Society of Ophthalmology Joint Meeting, New Orleans, LA
Research: Investigators studied the effect of Phototrop® on 106 patients in the early stages of age-related macular degeneration (AMD). The objective of the double-blind, placebo-controlled, single-center study carried out in Hungary was to determine how Phototrop influenced visual functions of patients ages 55 to 70 years with early AMD after 12 months of treatment compared to the placebo group. The study was also aimed at evaluating changes in fundus alterations or the drusen-covered areas. Finally, the safety of the product was considered.
Results: The researches found that the patients experienced a statistically significant decrease in drusen (yellow deposits that accumulate under the retina). They concluded that the findings justify an assumption that an appropriate combination of mitotropic compounds (those that influence mitochondrial metabolism) improves visual functions in early AMD and diminishes the risk of vision loss associated with more advanced stages of the disease.